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will be located in patient accessible areas around the unit to ensure
anonymity. Based upon admission rates, it is anticipated that data
collection will be complete by December. Descriptive statistics will
be used to evaluate items on the OPPQNCS, return rates will be
calculated, and staff will be polled as to any difﬁculty approaching
patients.
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MULTIDISCIPLINARY CLINICAL INITIATIVES TO DECREASE THE RISK
OF ETHICAL DILEMMAS
Neumann, J.L., Trevino, C., Hosing, C., Champlin, R. The University
of Texas MD Anderson Cancer Center, Houston, TX
Blood and Marrow Transplantation (BMT) healthcare providers
are confronted by a number of clinical situations that may chal-
lenge their technical skills, intellect, as well as beliefs, values and
principles. Having a professional responsibility to advocate for
patients, practitioners may have to come to terms with competing
ethical principles presented by differences in resources allocation,
religious beliefs, and societal mores. BMT care is unique in that
patients present with a life threatening illness, if untreated. In
addition, many of the interventions for control or cure tend to be
very aggressive and can greatly impact the individual’s quality of
life. The uncertainty related to the treatment options and out-
comes may also lead to difﬁculty in decisions making and potential
ethical dilemmas.
The purpose of this poster or presentation will be to identify
clinical initiatives, which have been successful in preventing or
resolving ethical dilemmas challenging the patient/family and the
healthcare team. These ethical issues include: advanced level of
appropriate care; informed consent; do not resusciate; and discon-
tinuation of medically inappropriate care. Clinical initiatives that
are currently being utilized include: ethics rounds; informal ethics
consult; advanced directive taskforce; care conferences; self-care
and caregiver agreements; and creation of a compliance algorithm/
pathway. Results of nurse survey examining the impact of ethics
rounds will be presented, as well as information about institutional
ethics consults. Copies of self-care and caregiver agreements and
educational material about advanced directives for high risk pa-
tients will be provided.
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HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM DISTRESS IN
PATIENTS UNDERGOING NON-MYELOABLATIVE (NST) VERSUS MY-
ELOABLATIVE (MT) ALLOGENEIC PERIPHERAL BLOOD STEM CELL
TRANSPLANTATION (PBSCT)
Bevans, M.1, Marden, S.1, Leidy, N.2, Soeken, K.3, Rivera, P.1, Cusack,
G.1, Mayberry, H.1, Bishop, M.4, Barrett, J.5 1. National Institues of
Health, Bethesda, MD; 2. MEDTAP International, Bethesda, MD; 3.
University of Maryland, Baltimore, MD; 4. National Cancer Institute,
Bethesda, MD; 5. National Heart, Lung, and Blood Institute, Bethesda,
MD
We prospectively examined health-related quality of life
(HRQL) and symptom distress (SD) in adult patients with hema-
tologic diseases undergoing PBSCT from HLA-identical sibling
donors receiving a ﬂudarabine/cyclophosphamide (CY) regimen
NST with unmanipulated cells (n  40), or a CY-total body
irradiation regimen MT with T-cell depletion (n  36). Generic
HRQL was measured by the physical (PCS) and mental (MCS)
summary scores of the Medical Outcomes Study Short Form-36
(SF-36). The Functional Assessment of Cancer Therapy-General
(FACT-G) and Bone Marrow Transplant (FACT-BMT; FACT-
G  BMT subscale) total scores were used to measure condition-
and treatment-speciﬁc HRQL, respectively. Higher scores indicate
better HRQL. SD was measured by the Symptom Distress Scale
(SDS). Higher scores indicate a greater level of SD. Subjects
completed surveys pre-treatment (FACT-G; SF-36; SDS) and on
days 0 (FACT-BMT; SDS), 30 and 100 (FACT-BMT; SF-36;
SDS). To compare HRQL (FACT-BMT, PCS, MCS) between
MT and NST, mixed linear modeling was used taking into account
the correlation between repeated measurements within subjects
over time. Due to group baseline demographic and clinical differ-
ences, baseline PCS and FACT-G served as covariates in the
respective models. To examine the relationship between SD and
HRQL at days 30 and 100, an exploratory analysis was conducted
using multiple regression with age, gender, ethnicity, group, and
disease status also included as predictors. Subjects (N  76) were
mostly male (67%), had ECOG status 0 or 1 (97%), and were in
remission or with stable disease (65%). HRQL scores showed no
difference between groups across time and no effect for group.
HRQL improved signiﬁcantly (p  0.05) in both groups over time
with higher scores at day 100 versus days 0 and 30. At days 30 and
100, SD had the highest beta weight contributing signiﬁcantly (p
0 .001) to the variance of HRQL scores and those with lower SD
scores had higher HRQL scores (Table). For the set of predictors,
the variance explained in HRQL ranged from 43% to 72% (Ta-
ble). Results suggest NST and MT have a similar effect on HRQL
during the ﬁrst 100 days post-transplant, despite the greater inten-
sity of the MT conditioning regimen. Lower SD is associated with
better HRQL and is an important contributor to its prediction
during the ﬁrst 100 days following allogeneic PBSCT.
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UNIQUE ANTI-EMETIC MANAGEMENT IN THE PEDIATRIC BONE MAR-
ROW TRANSPLANT PATIENTS
Smith, A., Smith, C., Youssef, S., Andrews, L., Olson, E., Gonzalez-
Ryan, L. Children’s Healthcare of Atlanta, AFLAC Cancer Center,
Atlanta, GA
Bone marrow transplantation (BMT) requires a stringent prepar-
ative regimen that results in a multitude of adverse effects. One of
the most distressing effects for these patients is chemotherapy-
induced nausea and vomiting (CINV). BMT patients require close
monitoring and thorough assessments, especially when suffering a
stressful side effect. Nurses should be knowledgeable of all possible
anti-emetic therapies. Routine anti-emetics include 5-HT3 recep-
tor antagonist, dopamine receptor antagonist, benzodiazepine, an-
ti-histamine and steroid. Different combinations of the above-
mentioned medications have been used in preventing or
controlling CINV and have been effective in majority of the time.
However, there are situations that patients will suffer from persis-
tent CINV. We described a unique experience in our pediatric
BMT patients in whom a combination of diphenhydramine
(Benadryl), lorazepam (Ativan), and dexamethasone (Decadron)
(BAD) was administered (modiﬁed from Dix SP et al, Bone Mar-
row Transplant, 1999). Patients received this mixture as a contin-
uous infusion and with patient-controlled boluses for persistent
CINV control. A total of 10 patients received the BAD drip during
the BMT course. Even with the continuous infusion, the accumu-
lated daily amount of each medication patient received was actually
lower than the total dose when each medication was given at
scheduled intervals. All patients experienced improved CINV
Table. Signiﬁcant Predictors of HRQL at Days 30 and 100
FACT-BMT PCS MCS
Beta Beta Beta
Day 30
Symptom distress .74† .61† .53†
Treatment group
(1  MT; 2 
NST) .22* — —
Gender (female) — .21* .28*
R2 (adj.R2) .61 (.56) .50 (.44) .43 (.36)
Day 100
Symptom distress .76† .55† .44†
Ethnicity (white) .32* — —
Age — .44† —
R2 (adj.R2) .72 (.67) .47 (.39) .46 (.37)
*P  .05; †P  .001.
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without any adverse reactions. The expected outcome was to for-
mulate an educational tool for nurses to instruct proper dosage
parameters, dose adjustment requirements, and side effects to be
aware of. An algorithm was created and posted in the nursing
medication room and handouts were printed for patients and
families with a list of possible adverse effects of the BAD drip. With
the knowledge of additional anti-emetic therapies, pediatric BMT
nurses will be better prepared to act on behalf of their BMT
population experiencing intractable nausea and vomiting.
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RE-EVALUATING A PATIENT SAFETY PROGRAM IN AN ONCOLOGY
NURSING SETTING
Marzan, A.B., Canlas, D., Cooke, S., Gerst, J., Nguyen, M.-L., Page-
Pettus, L. University of Texas M.D.Anderson Cancer Center, Houston,
TX
Keeping a patient safe and free from falls in the hospital setting
is an ongoing challenge for nurses and the health care team.
Therefore, fall prevention is a major component of our institu-
tion’s oncology patient safety program.
In the literature, the majority of studies address falls in persons
over the age of 70. Our patient population with cancer is younger,
35 to 60 years old, and has other factors involved; the disease
process itself, medications, weakness and fatigue, to name a few.
We decided to ﬁrst deﬁne our patient population’s risk factors and
then develop a program that would decrease falls within the
younger, oncology population.
Our plan included identifying patients at risk, revising our policy,
enhancing assessment and reassessment methods, providing new
visual alerts for patients at risk, and upgrading staff, patient and
family education programs.
These changes were piloted on 8 inpatient units for one month.
No falls were reported during this time frame. After the successful
pilot, over 1,500 health care workers received training to the
revised patient safety plan. The program was then implemented
house-wide. It was thought that these changes would continue to
eliminate falls.
However, outcome metrics, utilizing institutional incident re-
ports, indicated otherwise. Data analysis revealed no house-wide
culture change occurred. The number of inpatient falls/1,000 hos-
pital days remained the same as before the pilot.
The nursing staff on 3 leukemia units then decided to utilize a
simple Quality Improvement tool, the “OOPS Monitor” (Oppor-
tunity for Outstanding Patient Safety) to gather data. This data
revealed multi-factorial root causes underlying modest policy com-
pliance.
These results were shared with the nursing staff through focus
groups where additional data was collected. The staff identiﬁed
several issues related to non-use of the program elements. Each of
the 3 units was asked to develop an action plan in response to the
data. These action plans resulted in the implementation of a Mul-
tidisciplinary Fall Prevention Consult Team whose goal is to mon-
itor compliance and keep safety awareness at a maximum level.
Monthly monitoring will continue with timely feedback to unit
staff members and the institution.
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AN EMERGING CHALLENGE: NURSING SKIN CARE OF BONE MARROW
TRANSPLANT PATIENTS WITH MYCOSIS FUNGOIDES
Huynh, C.D., Mishaw, K., Neumann, J., Donato, M. The University of
Texas M.D. Anderson Cancer Center, Houston, TX
Nursing skin care for Mycosis Fungoides (MF)/ Sezary Syn-
drome patients has always been a challenge because of the risk of
chronic skin infection with staph species and subsequent systemic
infections.
Mycosis Fungoides/ Sezary Syndrome is a cutaneous T-cell lym-
phoma. Its clinical skin involvement is often initially mistaken for
eczema, psoriasis, or other types of T-cell lymphomas. The disease
remains indolent for many years before actual diagnosis. The
prognosis of these patients is based on the extent of disease at its
stage. Among various topical and systemic therapies, bone marrow
transplant emerges recently as a non-conventional treatment op-
tion. Because of the scarcity of BMT experience with patients who
have MF, standardized nursing guidelines for skin care in these
patients are yet established. Additional challenges arise, when
BMT patients face the complications of skin Graft-versus-Host
Disease (GVHD).
The Bone Marrow Transplant (BMT) department of our center
identiﬁed the nursing responsibility with skin care for these pa-
tients to establish the standard of nursing skin care for these
patients that is most effective. Generally, this program reviews the
clinical manifestations of the Mycosis Fungoides, its conventional
and non-conventional treatments, including BMT. Speciﬁcally, it
analyzes BMT patients with MF at our institution, focusing on
various nursing skin care methods, including sterile Central Ve-
nous Catheter dressing change techniques. A case study will also be
presented. In addition, the project informs current clinical trials
and examines the research at our institution that focuses on estab-
lishing BMT protocols for MF patients. The effectiveness of nurs-
ing skin care is measured by progressive healing of tissues and
decrease in the size of lesions, effective application of combination
of dressings, infection control, pain management, and the quality
of life of these patients.
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A REFERENCE GUIDE TO SEAMLESS CARE: THE BLOOD AND MARROW
TRANSPLANT COORDINATOR ORIENTATION MANUAL
Morse, R., Smith, B., Calamusa, J., Brion, C., Trulock, J., Harris, S.
UTMD Anderson Cancer Center, Houston, TX
Transitioning the blood and marrow transplant (BMT) patient
from the outpatient clinic to the inpatient setting in a large com-
prehensive cancer center can be a challenging and complex process.
M. D. Anderson Cancer Center BMT Department performs over
600 transplants each year, including autologous, allogeneic, and
sygeneic transplants. Currently, the transplant center employs ﬁve
related BMT coordinators. Each coordinator is responsible for
multiple physicians working with different diseases. The coordi-
nators deal with various diseases, hence, work-ups range from the
very simple patient evaluation and assessment to the complex
patient. Because of the variety of tests necessary, it was found that
work-ups were not always 100% complete. From there it was
determined that in order to provide consistent, accurate informa-
tion the ﬁrst time around, a resource manual was needed for the
current coordinators and new coordinators to utilize as a reference.
This would also help facilitate a simpler way of verifying what was
needed for each individualized patient work-up.
The reference evolved into the BMT Coordinator Orientation
Manual. The manual outlines each test needed for a speciﬁc disease
process. This is done using written instructions and sample work-
ups. The manual includes instructions for HLA typing of patient/
normal donor, donor work-ups, as well as detailed work-ups for
patients with various disease processes. The job description for the
BMT Nurse Transplant Coordinator and the policies and proce-
dures referring to the patient’s pre-transplant coordination process
are also included.
The manual is used on a regular basis by the coordinators to
provide consistent, accurate information without having to dupli-
cate orders on the same patient. Insisting on consistent, accurate
information aids in a seamless BMT admission process for the
transplant patient.
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LEADING LEADERS AT ONE OF THE LARGEST TRANSPLANT PROGRAMS
IN THE COUNTRY
Adornetto, D., Stary, S.J., Sorensen, S., Neumann, J., Johnston, P.
UTMD Anderson Cancer Center, Houston, TX
The Blood and Marrow Transplant patient’s journey through a
blood and marrow transplant program should be a seamless tran-
sition from the community, to the outpatient setting, to the inpa-
tient unit and back to the outpatient center. The various processes
that enable the journey to occur without interruption are one of
the many responsibilities of the leadership team. On a weekly basis,
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